Terms ending in 2038
Every in-force patent on Amgen Inc.'s record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US D974,547 | Handheld Drug Delivery Device In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 11,046,680 | Heteroaryl-Substituted Triazoles as Apj Receptor Agonists In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 11,059,908 | Low-Viscosity Antigen Binding Proteins and Methods of Making Them In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 12,723,248 | RNAi Constructs for Inhibiting ASGR1 Expression and Methods of Use Thereof In force · Medium confidence | Amgen Inc. | In force | Medium confidence | |
| US 10,517,954 | Pegylated Carfilzomib Compounds In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 12,617,853 | Low PH Pharmaceutical Composition Comprising T Cell Engaging Antibody Constructs In force · Medium confidence | Amgen Inc. | In force | Medium confidence | |
| US 10,905,772 | Method of Treating or Ameliorating Metabolic Disorders Using GLP-1 Receptor Agonists Conjugated to Antagonists for Gastric Inhibitory Peptide Receptor (GIPR) In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 11,220,541 | CCL20 as a Predictor of Clinical Response to IL23-Antagonists In force · High confidence | MedImmune, LLC | In force | High confidence | |
| US 10,991,458 | System and Method for Detecting Activation of a Medical Delivery Device In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 11,200,298 | Reducing Probability of Glass Breakage in Drug Delivery Devices In force · High confidence | Amgen Inc. | In force | High confidence | |
| 91 more term ends in 2038 · Pro | |||||
10 of 101 patents shown. Soonest term end first, then patent number.
Pro members see all 101.
92 of these are in force and held by Amgen Inc..
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.